There are several treatments for cancer, including medication, surgery, chemotherapy, radiation therapy, and targeted therapy. Although these methods are common among cancer treatments, they can cause side effects such as resistance to treatment and damage to non-cancerous cells, and other adverse effects on the cells. This study aimed to evaluate the apoptotic activity of the CpsA-CpsC-L-ACAN fusion peptide against the HeLa cancer cell line. The rate of primary apoptosis delayed apoptosis and necrosis in HeLa Cells with a concentration of 64 μg/mL of the fusion protein was significantly increased compared to cases not treated with recombinant protein. Apoptosis of cancer cells without fusion protein and cancer cells increased from 4 to 80% after exposure to the recombinant fusion protein, which increased 20-fold apoptosis. The results showed that the percentage of cells treated with recombinant protein at a concentration of 64 μg/mL with total apoptosis was 80% and increased by 20 folds compared to untreated cells. The results showed that the recombinant protein with the anticancer sequence can inhibit the proliferation of the HeLa cancer cell line and induce apoptosis. Therefore, it could be used as prevention a vaginal cream to inhibit uterine cancer.

有几种癌症治疗方法，包括药物治疗、手术、化学疗法、放射疗法和靶向疗法。尽管这些方法在癌症治疗中很常见，但它们会引起副作用，例如对治疗产生抵抗力和对非癌细胞的损伤，以及对细胞的其他不利影响。本研究旨在评估 CpsA-CpsC-L-ACAN 融合肽对 HeLa 癌细胞系的凋亡活性。与未用重组蛋白处理的病例相比，融合蛋白浓度为64 μg/mL的HeLa细胞的原发性细胞凋亡延迟细胞凋亡和坏死率显着增加。暴露于重组融合蛋白后，没有融合蛋白的癌细胞和癌细胞的凋亡率从 4% 增加到 80%，这使细胞凋亡增加了 20 倍。结果显示，与未处理的细胞相比，用浓度为 64 μg/mL 的重组蛋白处理的细胞总凋亡率为 80%，增加了 20 倍。结果表明，具有抗癌序列的重组蛋白可以抑制HeLa癌细胞系的增殖，并诱导细胞凋亡。因此，它可以作为一种预防子宫癌的阴道乳膏。